Human Cell Based Efficacy Models Patents: Leaders & White Space 2026
Human Cell Based Efficacy Models: Patents Behind Organoid, iPSC and Primary Cell Assays
Filings peaked in 2021 at 267 and fell 43% by 2024 (267→151) the most recent complete comparison the dataset supports — 2025 and 2026 are still filling in under an 18-month publication lag. Annual filings rose from 196 in 2017 to a peak of 267 in 2021, then declined to 151 by 2024 — a 43% drop over that three-year span. Counts for 2025 and 2026 are shown but understated, since publication typically lags filing by around 18 months.
- 1ATYR PHARM INC266
- 2PANGU BIOPHARMA LTD253
- 3AGENCY FOR SCI TECH & RES206
- 4SIGILON THERAPEUTICS INC175
- 5FATE THERAPEUTICS INC123
See the full human cell based efficacy models analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common Questions on This Landscape
Who holds the most patents on human cell based efficacy models?
One assignee leads the ranking with 266 records, well ahead of the fifth-place holder at 123 and the tenth-place holder at 70. The top 5 assignees combined account for 31.6% of all 3,239 records in scope, and the top 10 combined reach 45.8%. That leaves the majority of the corpus distributed across a long tail of smaller filers, so leadership at the top does not mean the field is closed to new entrants.
Is patent filing activity in this field growing or shrinking?
Filings rose from 196 in 2017 to a peak of 267 in 2021, then fell to 151 by 2024 — a 43% decline over that three-year window, which is the most recent period the dataset treats as complete. Counts shown for 2025 and 2026 are understated because patent publication typically lags filing by around 18 months, so it is too early to call the field in decline based on those years alone. The safest reading is that the field passed a filing peak in 2021 and has since settled to a lower but still active rate.
What technology areas dominate the patent claims in this space?
C12N, covering microorganisms and genetic engineering, appears in 71.7% of all 3,239 records, and A61K, medicinal preparations, appears in 52.2%. Because a single filing can carry multiple IPC classes, these percentages add up to more than 100% and should not be summed. Assay-methodology classes such as G01N (material analysis and testing) and C12M (bioreactors and culture apparatus) trail well behind at 17.3% and 7.5%, indicating the bulk of claim activity sits on cell derivation and formulation rather than on test-method design.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Human Cell Based Efficacy Models covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.